Psychiatry Investig.
2008 Sep;5(3):142-147.
Triple Reuptake Inhibitors: A Premise and Promise
- Affiliations
-
- 1Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA. pae@catholic.ac.kr
- 2Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.
Abstract
- On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these drugs. Research suggests that they may have a role in treating depressive disorders, and it is plausible they may have potential efficacy in obesity, addiction, and pain syndromes. The current review describes some of the molecules in development presently and explores the research relevant to possible clinical uses for this class of medications.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors
- Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors
- Pharmacological Treatment of Depression
- Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms
- Improvement of Post Stroke Echolalia after Using Selective Serotonin Reuptake Inhibitors
